Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection

Journal of Infectious Diseases

Volumn 203, Issue 4, 2011, Pages 442-451

  Meditz, Amie L ^a   MaWhinney, Samantha ^b   Allshouse, Amanda ^b   Feser, William ^b   Markowitz, Martin ^c   Little, Susan ^d   Hecht, Richard ^e   Daar, Eric S ^f   Collier, Ann C ^g   Margolick, Joseph ^h   Kilby, J Michael ^i,o   Routy, Jean Pierre ^j   Conway, Brian ^k   Kaldor, John ^l   Levy, Jay ^d   Schooley, Robert ^c   Cooper, David A ^l   Altfeld, Marcus ^m   Richman, Douglas ^c,n   Connick, Elizabeth ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^j MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m Partners AIDS Research Center   (United States)

ⁿ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIARRHEA; EUROPEAN AMERICAN; FEMALE; FEVER; GEOGRAPHIC DISTRIBUTION; HAIRY LEUKOPLAKIA; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAVENOUS DRUG ABUSE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PRIMARY INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; SEBORRHEIC DERMATITIS; SEROCONVERSION; SEX DIFFERENCE; SEXUAL BEHAVIOR; THRUSH; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINA CANDIDIASIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; GEOGRAPHY; HIV INFECTIONS; HIV-1; HUMANS; MALE; NORTH AMERICA; RISK FACTORS; RNA, VIRAL; SEX FACTORS; TREATMENT OUTCOME;

EID: 79751497988     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq085     Document Type: Article

References (43)

1. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80. (Pubitemid 30194468)
2. Daar ES, Little S, Pitt J, et al. Diagnosis of primary HIV-1 infection. Los Angeles County primary HIV infection recruitment network. Ann Intern Med 2001; 134:25-9. (Pubitemid 32037340)
3. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-64.
4. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5. (Pubitemid 32204989)
5. Hubert JB RC, Boufassa F, Delfraissy JF, Meyer L. Gender, disease progression and response to HAART. Int Conf AIDS 2002. abstract no. ThOrC1448.
6. + cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997; 11:1071-3.
7. Touloumi G, Pantazis N, Babiker AG, et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18:1697-705.
8. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-72. (Pubitemid 29411351)
9. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, GreenblattRM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313-22.
10. Prins M, Robertson JR, Brettle RP, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-4.
11. + lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003; 26:101-7.
12. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-8. (Pubitemid 28414995)
13. Apuzzo LG, Vaida F, Gallant JE, et al. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr 2009; 50:267-75.
14. HIV/AIDS Surveillance - General Epidemiology (through 2007). Vol. 2010. Atlanta, GA: Centers for Disease Control Prevention, 2010.
15. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-9.
16. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
17. Gray RH, Li X, Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209-15. (Pubitemid 38457245)
18. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-Infected persons in care. J Infect Dis 2009; 199:991-8.
19. McNaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32:499-505. (Pubitemid 36423121)
20. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000; 25:115-23.
21. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96-103.
22. Giordano TP, White AC Jr, Sajja P, et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003; 32: 399-405. (Pubitemid 36363154)
23. McNaghten AD. Gender disparity in HIV treatment and AIDS opportunistic illnesses (OI). The XV International AIDS Conference. Bangkok, Thailand: 2004.
24. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168:532-40.
25. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1:224-31.
26. Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34:184-90. (Pubitemid 37248915)
27. Cozzi Lepri A, Pezzotti P, Dorrucci M. Phillips AN, Rezza G. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ 1994; 309:1537-42.
28. Woldemichael G, Christiansen D, Thomas S, Benbow N. Demographic characteristics and survival with AIDS: health disparities in Chicago, 1993-2001. Am J Public Health 2009; 99:S118-23.
29. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-23. (Pubitemid 32549862)
30. Murray CJ, Kulkarni SC, Michaud C, et al. Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med 2006; 3:e260.
31. Adler NE, Newman K. Socioeconomic disparities in health: pathways and policies. Health Aff (Millwood) 2002; 21:60-76.
32. Connick E, MaWhinney S, Wilson CC, Campbell TB. Challenges in the study of patients with HIV type 1 seroconversion. Clin Infect Dis 2005; 40:1355-7. (Pubitemid 40570248)
33. Centers for Disease Control and Prevention. Fact sheet: MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations, http://www.cdc.gov/ hiv/topics/surveillance/resources/factsheets/pdf/mmwr-incidence.pdf. Accessed March 2009.
34. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
35. Smit C, Geskus R, Walker S, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-9. (Pubitemid 43884302)
36. Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22:89-95. (Pubitemid 350294882)
37. HIV AIDS in the United States: a picture of today's epidemic. http://www.cdc.gov/hiv/topics/surveillance/united-states.htm. Centers for Disease Control and Prevention. 2008.
38. AIDS surveillance - general epidemiology (through 2006). http://www.cdc.gov/hiv/topics/surveillance/resources/slides/epidemiology/index. htm. Centers for Disease Control and Prevention. 2008.
39. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-forgotten but not gone. N Engl J Med 2010; 362:967-70.
40. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999; 281:2305-15. (Pubitemid 29289823)
41. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43:III 40-52.
42. Berkman L, Epstein AM. Beyond health care-socioeconomic status and health. N Engl J Med 2008; 358:2509-10.
43. Mackenbach JP, Stirbu I, Roskam AJ, et al. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 2008; 358:2468-81. (Pubitemid 351793020)